Xceleron is moving to a new custom-built facility in Germantown, MD, which is expected to be fully operational by March 31. The move follows a $2.4 million investment from Albion Ventures and Solon Ventures.

The company is relocating senior analytical staff to Germantown from York, and hiring new staff in Maryland. Xceleron will retain a study design and project management presence in the UK. The facility is capable of providing a range of studies including absolute bioavailability, metabolism and general pharmacokinetic investigations. Xceleron plans to augment its analytical capability in Germantown with the latest in highly sensitive LC-MS/MS technology, creating a lab in which all forms of microtracer and microdose investigations can be conducted in one facility.

Xceleron chief executive officer Michael Butler said, “Our customers told us that they want access to the best analytical platforms in translational science. We are providing that access with the most experienced team in the business and in one highly efficient and purpose built location. This is a first-of-a-kind combination from Xceleron that we believe will add to our customers drive for Phase II readiness.”